BioSpace News Archive

Abbott will announce its first-quarter 2020 financial results on Thursday, April 16, 2020, before the market opens.

OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced an update on shareholder proxy voting in relation to the business combination with Curetis.

Dragonfly Therapeutics, Inc. (“Dragonfly”), today announced an expansion of its strategic collaboration with Merck, known as MSD outside the United States and Canada to discover, develop and commercialize a number of Dragonfly’s candidate natural killer (“NK”) cell engager immunotherapies for oncology, infectious disease, and immune disorders.

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced expanded access to its virtual ordering platforms and remote testing capabilities across its reproductive, oncology and organ transplant businesses.

Exact Sciences Corp. provided an update on the actions it is taking to support patients, employees, and public health initiatives in response to the coronavirus pandemic.

Soligenix, Inc. announced positive preliminary top-line results for its pivotal Phase 3 FLASH trial evaluating SGX301 in the treatment of cutaneous T-cell lymphoma.

System Order Will Bring the Benefits of MRI-guidance and On-table Adaptive Therapy to Patients Throughout the Region

Co-Diagnostics, Inc. announced that CoSara Diagnostics Pvt Ltd, its joint venture for manufacturing in India, has become the first and only Indian company to receive a license from the Central Drugs Standards Control Organisation to manufacture RT-PCR COVID-19 test kits.

Hansoh Pharmaceutical Group Company Limited announced that the National Medical Products Administration has granted marketing authorization for AMEILE once daily tablets for the treatment of patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer, who have progressed on or after other EGFR tyrosine kinase inhibitor therapy.

HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, reports its financial results and corporate update for the fourth quarter and full year 2019.